Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use

Immune checkpoint inhibition (ICI) is a promising cancer therapy, which has progressed rapidly from a preclinical concept to clinical implementation. Commonly considered targets in ICI are CTLA-4, PD-1/PD-L1, and LAG-3, and the list grows. As ICI is generally only beneficial for a subset of patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Lecocq, Quentin, Zeven, Katty, De Vlaeminck, Yannick, Martens, Sandrina, Massa, Sam, Goyvaerts, Cleo, Raes, Geert, Keyaerts, Marleen, Breckpot, Karine, Devoogdt, Nick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843898/
https://www.ncbi.nlm.nih.gov/pubmed/31569553
http://dx.doi.org/10.3390/biom9100548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843898/
https://www.ncbi.nlm.nih.gov/pubmed/31569553
http://dx.doi.org/10.3390/biom9100548

Ejemplares similares